Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing neurodegenerative disease candidates, (the "Company" or "Cognition") ...
Strength in Dolby Atmos and Dolby Vision, synergies from acquisitions and focus on shareholder returns make DLB an attractive investment opportunity.
Cognition Therapeutics also worked with Arjuna Ratnayaka, Ph.D. in the School of Clinical and Experimental Sciences at the University of Southampton to conduct an in vitro study showing the potential ...
Handelsbanken Fonder AB lowered its holdings in Dolby Laboratories, Inc. (NYSE:DLB – Free Report) by 23.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & ...